abm-1310
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 16, 2019 (NCT04190628)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068566 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05892653 | Phase 1 | Jun 30, 2023 | ABM Therapeutics, Inc., Capital Medical University |
| NCT05501912 | Phase 1 | Aug 24, 2022 | ABM Therapeutics, Inc., Huazhong University of Science and Technology |
| NCT04190628 | Phase 1 | Dec 16, 2019 | ABM Therapeutics, Inc., University of Texas at Houston |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ABM Therapeutics, Inc. | For profit | 3 | 3 | 1 | 2019 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1